RedHill Biopharma Ltd. RDHL
Set alert
0.45 USD +0.06 +16.55%
As of Nov 2, 3:59 PM ET
0.39 Day range 0.4707
0.38 52-week range 1.60
- YTD
- -56.12%
- 1 year
- -65.23%
- Open
- 0.39
- Prev close
- 0.3878
- Mkt cap
- 3.92M
- Vol
- 311.03K
- Avg vol
- 2.07M
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.39
- High
- 0.4707
- Forward P/E
- 210.67
- Beta
- 3.67
- Short ratio
- 0.37
- Inst. own
- 5.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 3, 2024
- 50-d avg
- 7.70
- 200-d avg
- 9.87
- 1y target
- 0.00
5Y chart
Events in this range
- Mar 23, 2023Split: 1 for 40
- Jun 12, 2023Earnings: 146.75; estimate 0; surprise —%
- Jan 2, 2024Earnings: —; estimate 0; surprise —%
- Jul 1, 2024Earnings: —; estimate 0; surprise —%
- Aug 20, 2024Split: 1 for 25
- Oct 3, 2024Earnings: —; estimate 0; surprise —%
Signals (46)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 26, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 4 weeks ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| RSI: Oversold | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| RSI: Oversold | Mar 10, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 24, 2025 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| SMA: Bearish | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 29, 2024 | 2 years ago |
| SMA: Bearish | Jan 22, 2024 | 2 years ago |
| SMA: Bearish | Jan 15, 2024 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| RSI: Oversold | Mar 13, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| RSI: Oversold | Nov 21, 2022 | 3 years ago |
| RSI: Oversold | Sep 12, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 18, 2022 | 4 years ago |
| SMA: Bullish | Jul 11, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 11, 2022 | 4 years ago |
| SMA: Bearish | Apr 11, 2022 | 4 years ago |
| RSI: Oversold | Apr 11, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 8.09M
- Enterprise value
- 76.44B
- Trailing P/E
- 0.00
- Forward P/E
- 210.67
- PEG ratio
- 0.00
- Price / sales
- 2.18
- Price / book
- 121.54
- EPS (TTM)
- -302.63
- Beta
- 3.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.71M
- Revenue growth
- -28.40%
- Free cash flow
- -5.39M
- Total cash
- 7.28M
- Total debt
- 558.00K
- Return on equity
- -1708.61%
- Shares outstanding
- 1.28M
- Short % of float
- 0.49%
- 50-day average
- 7.70
- 200-day average
- 9.87
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Oct 3, 2024
Expected Oct 3, 2024. Consensus EPS estimate 0.00.
Financials — quick view
RDHL Revenue — quarterly 1.80M
RDHL Net income — quarterly 761.00K
RDHL EPS — quarterly -100.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 3, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 1, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Jan 2, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
| Jun 12, 2023 | Mar 1, 2023 | 0.00 | 146.75 | — | — |
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- Website
- redhillbio.com
News
- Redhill Biopharma Announced Confirmation Of RHB-204's Killing Capability On Mycobacterium Avium Subspecies Paratuberculosis And Its Comparability To RHB-104 MAP-Killing
- Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- RedHill Biopharma’s Partner University Of Oklahoma Receives $2.9M In Funding From National Cancer Institute To Study, In Clinical Trials, Whether RedHill's Opaganib, Given After CAR T-Cell Therapy, May Help Immune Cells Fight Cancer More Effectively
- $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
- Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL)
- RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
- Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)
- RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
- 12 Health Care Stocks Moving In Monday's Intraday Session
Your note
Sign in to keep a note on RDHL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federation Des Caisses Desjardins Du Quebec | 0.31% | 3,992 | 25.23K | Sep 29, 2024 |
| Rhumbline Advisers | 0.08% | 979 | 6.19K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.03% | 396 | 2.50K | Sep 29, 2024 |
| Morgan Stanley | 0.01% | 180 | 1.14K | Sep 29, 2024 |
| Capital Performance Advisors LLP | 0.00% | 5 | 31 | Sep 29, 2024 |
| Group One Trading, L.P. | 0.00% | 22 | 139 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 41 | 259 | Sep 29, 2024 |